MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOVFree Report) in a report published on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Stock Down 1.5 %

MediciNova stock opened at $1.31 on Friday. The company has a market cap of $64.26 million, a price-to-earnings ratio of -7.71 and a beta of 0.70. The firm’s fifty day moving average is $1.39 and its 200 day moving average is $1.43. MediciNova has a 52-week low of $1.26 and a 52-week high of $2.66.

MediciNova (NASDAQ:MNOVGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). On average, equities research analysts anticipate that MediciNova will post -0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MediciNova stock. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of MediciNova, Inc. (NASDAQ:MNOVFree Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 19,000 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. 9.90% of the stock is owned by hedge funds and other institutional investors.

MediciNova Company Profile

(Get Free Report)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

Featured Articles

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.